P13285 (LMP2_EBVB9) Reviewed, UniProtKB/Swiss-Prot
Last modified
April 3, 2013.
Version 80.
History...
Names·Attributes·General annotation·Ontologies·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Latent membrane protein 2 Alternative name(s): Terminal protein | ||
| Gene names |
| ||
| Organism | Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) [Reference proteome] | ||
| Taxonomic identifier | 10377 [NCBI] | ||
| Taxonomic lineage | Viruses › dsDNA viruses, no RNA stage › Herpesvirales › Herpesviridae › Gammaherpesvirinae › Lymphocryptovirus › ![]() | ||
| Virus host | Homo sapiens (Human) [TaxID: 9606] |
Protein attributes
| Sequence length | 497 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | Isoform LMP2A maintains EBV latent infection of B-lymphocyte, by preventing lytic reactivation of the virus in response to surface immunoglobulin (sIg) cross-linking. Acts like a dominant negative inhibitor of the sIg-associated protein tyrosine kinases, LYN and SYK. Also blocks translocation of the B-cell antigen receptor (BCR) into lipid rafts, preventing the subsequent signaling and accelerated internalization of the BCR upon BCR cross-linking. Serves as a molecular scaffold to recruit SYK, LYN and E3 protein-ubiquitin ligases, such as ITCH and NEDD4L, leading to ubiquitination and potential degradation of both tyrosines kinases. Possesses a constitutive signaling activity in non-transformed cells, inducing bypass of normal B lymphocyte developmental checkpoints allowing immunoglobulin-negative cells to colonize peripheral lymphoid organs. Ref.5 Ref.8 Isoform LMP2B may be a negative regulator of isoform LMP2A. Ref.5 Ref.8 |
| Subunit structure | Isoform LMP2A cytoplasmic N-terminal domain interacts with human SRC family protein tyrosine kinases SYK and LYN. Binds human ITCH, WWP2 and NEDD4L. Ref.6 Ref.9 |
| Subcellular location | Isoform LMP2A: Host cell membrane; Multi-pass membrane protein. Note: Isoform LMP2A is localized in plasma membrane lipid rafts. Ref.10 Ref.11 Isoform LMP2B: Host endomembrane system; Multi-pass membrane protein. Host cytoplasm › host perinuclear region. Note: Isoform LMP2B localizes to perinuclear regions. Ref.10 Ref.11 |
| Post-translational modification | Isoform LMP2A is phosphorylated on cytoplasmic N-terminal tyrosines residues, possibly by human LYN. Ref.4 Can be ubiquitinated by human ITCH and WWP2 on the N-terminus in a lysine-independent manner. |
| Miscellaneous | In healthy individuals, EBV typically establishes a persistent latent infection in which the virus can be detected in resting, nonproliferating peripheral B-lymphocytes. These latently infected cells express only 2 virally encoded genes, LMP2A and EBNA1. |
| Sequence similarities | Belongs to the herpesviridae LMP-2 family. |
Ontologies
Alternative products
| This entry describes 2 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform LMP2A (identifier: P13285-1) Also known as: TP1; This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform LMP2B (identifier: P13285-2) Also known as: TP2; The sequence of this isoform differs from the canonical sequence as follows: 1-119: Missing. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||
Molecule processing | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 497 | 497 | Latent membrane protein 2 | PRO_0000116280 | |||||
Regions | |||||||||
| Topological domain | 1 – 123 | 123 | Cytoplasmic Potential | ||||||
| Transmembrane | 124 – 144 | 21 | Helical; Potential | ||||||
| Topological domain | 145 – 147 | 3 | Extracellular Potential | ||||||
| Transmembrane | 148 – 168 | 21 | Helical; Potential | ||||||
| Topological domain | 169 – 177 | 9 | Cytoplasmic Potential | ||||||
| Transmembrane | 178 – 198 | 21 | Helical; Potential | ||||||
| Topological domain | 199 – 211 | 13 | Extracellular Potential | ||||||
| Transmembrane | 212 – 232 | 21 | Helical; Potential | ||||||
| Topological domain | 233 – 241 | 9 | Cytoplasmic Potential | ||||||
| Transmembrane | 242 – 262 | 21 | Helical; Potential | ||||||
| Topological domain | 263 – 267 | 5 | Extracellular Potential | ||||||
| Transmembrane | 268 – 288 | 21 | Helical; Potential | ||||||
| Topological domain | 289 – 296 | 8 | Cytoplasmic Potential | ||||||
| Transmembrane | 297 – 317 | 21 | Helical; Potential | ||||||
| Topological domain | 318 | 1 | Extracellular Potential | ||||||
| Transmembrane | 319 – 339 | 21 | Helical; Potential | ||||||
| Topological domain | 340 – 354 | 15 | Cytoplasmic Potential | ||||||
| Transmembrane | 355 – 375 | 21 | Helical; Potential | ||||||
| Topological domain | 376 – 388 | 13 | Extracellular Potential | ||||||
| Transmembrane | 389 – 409 | 21 | Helical; Potential | ||||||
| Topological domain | 410 – 422 | 13 | Cytoplasmic Potential | ||||||
| Transmembrane | 423 – 443 | 21 | Helical; Potential | ||||||
| Topological domain | 444 – 449 | 6 | Extracellular Potential | ||||||
| Transmembrane | 450 – 470 | 21 | Helical; Potential | ||||||
| Topological domain | 471 – 497 | 27 | Cytoplasmic Potential | ||||||
| Motif | 97 – 101 | 5 | PPPPY WW-binding | ||||||
Amino acid modifications | |||||||||
| Modified residue | 112 | 1 | Phosphotyrosine; by host Potential | ||||||
Natural variations | |||||||||
| Alternative sequence | 1 – 119 | 119 | Missing in isoform LMP2B. | VSP_016139 | |||||
Experimental info | |||||||||
| Mutagenesis | 74 | 1 | Y → F: Loss of interaction with human SYK. Ref.7 | ||||||
| Mutagenesis | 85 | 1 | Y → F: Loss of interaction with human SYK. Ref.7 | ||||||
| Mutagenesis | 112 | 1 | Y → F: Complete loss of phosphorylation. Ref.7 | ||||||
Sequences
| ||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome." Laux G., Perricaudet M., Farrell P.J. EMBO J. 7:769-774(1988) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. |
| [2] | "Two related Epstein-Barr virus membrane proteins are encoded by separate genes." Sample J., Liebowitz D., Kieff E. J. Virol. 63:933-937(1989) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LMP2A AND LMP2B). |
| [3] | "DNA sequence and expression of the B95-8 Epstein-Barr virus genome." Baer R., Bankier A.T., Biggin M.D., Deininger P.L., Farrell P.J., Gibson T.J., Hatfull G., Hudson G.S., Satchwell S.C., Seguin C., Tuffnell P.S., Barrell B.G. Nature 310:207-211(1984) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM LMP2A). |
| [4] | "An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase." Longnecker R., Druker B., Roberts T.M., Kieff E. J. Virol. 65:3681-3692(1991) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION. |
| [5] | "An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking." Miller C.L., Lee J.H., Kieff E., Longnecker R. Proc. Natl. Acad. Sci. U.S.A. 91:772-776(1994) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION. |
| [6] | "Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases." Miller C.L., Burkhardt A.L., Lee J.H., Stealey B., Longnecker R., Bolen J.B., Kieff E. Immunity 2:155-166(1995) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH HUMAN SYK AND LYN. |
| [7] | "Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency." Fruehling S., Swart R., Dolwick K.M., Kremmer E., Longnecker R. J. Virol. 72:7796-7806(1998) [PubMed] [Europe PMC] [Abstract] Cited for: MUTAGENESIS OF TYR-74; TYR-85 AND TYR-112. |
| [8] | "Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals." Caldwell R.G., Wilson J.B., Anderson S.J., Longnecker R. Immunity 9:405-411(1998) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION. |
| [9] | "Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases." Winberg G., Matskova L., Chen F., Plant P., Rotin D., Gish G., Ingham R., Ernberg I., Pawson T. Mol. Cell. Biol. 20:8526-8535(2000) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH HUMAN ITCH AND NEDD4L. |
| [10] | "Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR." Dykstra M.L., Longnecker R., Pierce S.K. Immunity 14:57-67(2001) [PubMed] [Europe PMC] [Abstract] Cited for: SUBCELLULAR LOCATION. |
| [11] | "Epstein-Barr virus latent membrane protein 2B (LMP2B) co-localizes with LMP2A in perinuclear regions in transiently transfected cells." Lynch D.T., Zimmerman J.S., Rowe D.T. J. Gen. Virol. 83:1025-1035(2002) [PubMed] [Europe PMC] [Abstract] Cited for: SUBCELLULAR LOCATION. |
| [12] | "Lysine-independent ubiquitination of Epstein-Barr virus LMP2A." Ikeda M., Ikeda A., Longnecker R. Virology 300:153-159(2002) [PubMed] [Europe PMC] [Abstract] Cited for: UBIQUITINATION. |
| [13] | "Allele-dependent similarity between viral and self-peptide presentation by HLA-B27 subtypes." Fiorillo M.T., Ruckert C., Hulsmeyer M., Sorrentino R., Saenger W., Ziegler A., Uchanska-Ziegler B. J. Biol. Chem. 280:2962-2971(2005) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 236-244. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMBL GenBank DDBJ | M24212 mRNA. Translation: AAA45887.1. Y00835 mRNA. Translation: CAA68762.1. V01555 Genomic DNA. No translation available. AJ507799 Genomic DNA. Translation: CAD53383.1. Sequence problems. AJ507799 Genomic DNA. Translation: CAD53382.1. Sequence problems. | ||||||||||||||||||||||||||||||||||||
| PIR | WMBELM. A30178. | ||||||||||||||||||||||||||||||||||||
| RefSeq | YP_401631.1. NC_007605.1. | ||||||||||||||||||||||||||||||||||||
3D structure databases | |||||||||||||||||||||||||||||||||||||
| PDBe RCSB PDB PDBj |
| ||||||||||||||||||||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||||||||||||||||||||
| MINT | MINT-6768292. | ||||||||||||||||||||||||||||||||||||
Protocols and materials databases | |||||||||||||||||||||||||||||||||||||
| StructuralBiologyKnowledgebase | Search... | ||||||||||||||||||||||||||||||||||||
Genome annotation databases | |||||||||||||||||||||||||||||||||||||
| GeneID | 3783751. | ||||||||||||||||||||||||||||||||||||
Phylogenomic databases | |||||||||||||||||||||||||||||||||||||
| ProtClustDB | CLSP2512497. | ||||||||||||||||||||||||||||||||||||
Family and domain databases | |||||||||||||||||||||||||||||||||||||
| InterPro | IPR010881. Herpes_LMP2. [Graphical view] | ||||||||||||||||||||||||||||||||||||
| Pfam | PF07415. Herpes_LMP2. 1 hit. [Graphical view] | ||||||||||||||||||||||||||||||||||||
| ProtoNet | Search... | ||||||||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||||||||
| EvolutionaryTrace | P13285. | ||||||||||||||||||||||||||||||||||||
Entry information
| Entry name | LMP2_EBVB9 | ||||||||
| Accession | Primary (citable) accession number: P13285 Secondary accession number(s): Q777H4, Q8AZK9 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Viral Protein Annotation Program | ||||||||
Relevant documents
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with
